In the companion to this article, Dr Ruiz et al 5 conducted an analysis of two prospective studies using wearable accelerometer-based evaluations to define patients' fitness through a new score known ...
Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
Morning Overview on MSN
New AI tool aims to predict small cell lung cancer treatment response
Researchers have built an AI-powered pathology tool designed to predict whether small cell lung cancer patients will respond ...
Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial Patients with mCRC exposed to FTD-TPI + ...
Opdivo plus Yervoy significantly improved PFS in MSI-H/dMMR metastatic CRC compared to Opdivo alone, with sustained separation of PFS curves. The combination therapy showed higher ORR and complete ...
- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% ...
Researchers have found in a negative trial that neoadjuvant chemotherapy did not improve disease-free survival compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results